CRDF - NASDAQ
Cardiff Oncology, Inc.
$1.51
+7.5%Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
At a Glance
Live SnapshotCardiff Oncology, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Cardiff Oncology, Inc. Income Statement
CRDF • NASDAQ
| Cardiff Oncology, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Jan 2006 | Jan 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||||||
593K | 683K | 488K | 386K | 359K | 366K | 245K | 378K | 505K | 381K | 313K | 280K | 259.2K | 450K | 257.7K | 265.7K | 650K | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||||||||||
(904K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (11.2M) | (597K) | (1.8M) | (1.7M) | (629K) | (15K) | (3.5M) | (1.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-311K | 683K | 488K | 386K | 359K | 366K | -10.9M | -219K | -1.3M | -1.3M | -316K | 265K | -3.2M | -1.5M | 257.7K | 265.7K | 650K | 0.0 | 0.0 | |
OPERATING INCOME | |||||||||||||||||||
(48.6M) | (49.3M) | (45.9M) | (40.3M) | (29.2M) | (19.5M) | (16.9M) | (16.2M) | (22.1M) | (38M) | (25M) | (15.2M) | (10.9M) | (5.3M) | (3.2M) | (5.6M) | (3.1M) | (4.4M) | (1.3M) | |
(14.2M) | (12.5M) | (13M) | (13.2M) | (11.8M) | (8.2M) | (5.8M) | (8M) | (14.2M) | (23M) | (14.4M) | (8.5M) | (7M) | (3.4M) | (2.3M) | (2M) | (2.2M) | (2.5M) | (651.7K) | |
(35.3M) | (36.9M) | (32.9M) | (27.1M) | (17.4M) | (11.2M) | (11.2M) | (8.2M) | (7.9M) | (15M) | (10.6M) | (6.7M) | (3.9M) | (1.9M) | (910.7K) | (3.7M) | (0.0) | (1.9M) | (619.6K) | |
-49M | -48.7M | -45.4M | -39.9M | -28.9M | -19.1M | -16.7M | -17.1M | -25.6M | -40.1M | -25.3M | -14.9M | -10.7M | -4.8M | -3M | -5.4M | -2.4M | -8M | -5.4M | |
PRE-TAX INCOME | |||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2K) | (0.0) | (25.4K) | (1M) | (1.4M) | (1.5M) | (843K) | (17K) | (0.0) | (56.6K) | (115.6K) | -90K | (0.0) | (0.0) | |
3.1M | 3.3M | 4.1M | 1.6M | 264K | 88K | 234.2K | 194K | -886.1K | -1.4M | -1.5M | -831K | -13.3K | 0.0 | -56.5K | -115.4K | 0.0 | 0.0 | 0.0 | |
-904K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -170K | -145K | -3K | (0.0) | (0.0) | (4K) | (0.0) | (0.0) | (830K) | (0.0) | (0.0) | |
3.1M | 3.2M | 4M | 1.2M | 564K | -221K | 264.3K | -72.5K | 689.1K | 941.9K | -2.2M | 619.7K | -1.1M | -6.7M | 699.4K | -69.9K | -90K | 155.6K | 6K | |
-45.9M | -45.4M | -41.4M | -38.7M | -28.3M | -19.3M | -16.4M | -16.5M | -24.9M | -39.2M | -27.5M | -14.3M | -11.8M | -11.6M | -2.3M | -5.3M | -2.5M | -7.8M | -5.4M | |
NET INCOME | |||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -262K | (617.6K) | (716K) | -296K | (1.8M) | (608.2K) | (17K) | (6.7M) | -737.6K | (69.9K) | -180K | (0.0) | (0.0) | |
-45.9M | -45.4M | -41.4M | -38.7M | -28.3M | -19.3M | -16.4M | -16.5M | -24.9M | -39.2M | -27.5M | -14.3M | -11.8M | -11.6M | -2.2M | -5.4M | -2.5M | -7.8M | -5.4M |
SEC Filings
CRDF - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 29, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 |
Related Guides
Continue your CRDF research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.